This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
See Cramer's multi-million dollar portfolio for FREE and get his new book Get Rich Carefully! Learn More

Adam Feuerstein

Senior Columnist

Before joining TheStreet in March 2001, Feuerstein covered business software for Upside.com. Prior to that he covered a variety of business beats, including technology and commercial real estate, at the San Francisco Business Times.


Feuerstein graduated from Emory University with a bachelor's degree in political science.


Adam Feuerstein
By This Author:
Page 4 of 556
Article

Endocyte Scores Double Win With Targeted Cancer Drug

By Adam Feuerstein

European regulators recommended Vynfinit's approval for ovarian cancer and a mid-stage lung cancer study was successful.

10:50AM 03/21/14

Article

Biotech Stock Mailbag: Amarin, Cytrx, Sangamo and 'Story Stocks'

By Adam Feuerstein

Biotech columnist Adam Feuerstein answers readers' questions about health care companies.

07:00AM 03/21/14

Article

Read This Twitter Chat About Gilead and the Cost of its Hep C Drug

By Adam Feuerstein

Bloomberg's Drew Armstrong and ISI Group's Mark Schoenebaum discuss Gilead, Sovaldi and the controversy of Medicaid reimbursement.

05:54PM 03/20/14

Article

Exact Sciences' Colon Cancer Screening Test Results Published in NEJM

By Adam Feuerstein

Cologuard was able to detect more cancer and pre-cancerous lesions than a comparator test but also caused more false positives.

07:05PM 03/18/14

Article

MannKind's Most Financially Conflicted Sell-Side Analyst Loves Afrezza

By Adam Feuerstein

When your job is helping MannKind sell stock, it's not hard to be a bull.

03:22PM 03/18/14

Article

Prosensa Making the Best of Inconsistent Drisapersen Data

By Adam Feuerstein

With its Big Pharma partner gone, Prosensa will probably try to conjure a good story to bring in front of the FDA.

11:03AM 03/18/14

Article

Galena Discloses SEC Investigation Focused on Stock-Touting Campaign

By Adam Feuerstein

The SEC investigation into Galena began in February, following an exclusive story by TheStreet.

10:06AM 03/18/14

Article

Intercept Pharma Drug Scores Pivotal Study Win Against Rare Liver Disease

By Adam Feuerstein

The company intends to seek accelerated approval in the U.S. for OCA, based on the positive results from the phase III study in PBC patients.

12:15AM 03/17/14

Article

New Heart Safety Report Caused Intercept Pharma's Friday Night Stumble

By Adam Feuerstein

Intercept discloses cardiovascular events reported in a study of the company's fatty liver disease drug.

08:04PM 03/14/14

Article

The Bull Case for Gilead Amidst Recent Hep C Sales Cliff Worries

By Adam Feuerstein

Gilead has transformed itself with tremendous success twice already and is now working on plan number three.

12:45PM 03/14/14

Page 4 of 556

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
DOW 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 +2.54 0.14%
NASDAQ 4,095.5160 +9.2910 0.23%

Brokerage Partners

Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs